Levo Therapeutics Receives Complete Response Letter From FDA for Its New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling